154 related articles for article (PubMed ID: 9058723)
21. Molecular cytogenetic analysis of RB-1 deletions in chronic B-cell leukemias.
Döhner H; Pilz T; Fischer K; Cabot G; Diehl D; Fink T; Stilgenbauer S; Bentz M; Lichter P
Leuk Lymphoma; 1994 Dec; 16(1-2):97-103. PubMed ID: 7696936
[TBL] [Abstract][Full Text] [Related]
22. Cytogenetic studies on prolymphocytic leukemia. 1. B-cell prolymphocytic leukemia.
Brito-Babapulle V; Pittman S; Melo JV; Pomfret M; Catovsky D
Hematol Pathol; 1987; 1(1):27-33. PubMed ID: 3509770
[TBL] [Abstract][Full Text] [Related]
23. A unique spectrum of p53 mutations in B-cell chronic lymphocytic leukemia distinct from that of other lymphoid malignancies.
Newcomb EW; el Rouby S; Thomas A
Mol Carcinog; 1995 Dec; 14(4):227-32. PubMed ID: 8519411
[TBL] [Abstract][Full Text] [Related]
24. Screening for mutations of Bcl10 in leukaemia.
Grimwade D; Du MQ; Langabeer S; Rogers J; Solomon E
Br J Haematol; 2000 Jun; 109(3):611-5. PubMed ID: 10886211
[TBL] [Abstract][Full Text] [Related]
25. Association of p53 gene and protein alterations with metastases in colorectal cancer.
Bertorelle R; Esposito G; Del Mistro A; Belluco C; Nitti D; Lise M; Chieco-Bianchi L
Am J Surg Pathol; 1995 Apr; 19(4):463-71. PubMed ID: 7694948
[TBL] [Abstract][Full Text] [Related]
26. Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53.
Christodoulopoulos G; Fotouhi N; Krajewski S; Reed JC; Alaoui-Jamali M; Panasci L
Cancer Lett; 1997 Dec; 121(1):59-67. PubMed ID: 9459175
[TBL] [Abstract][Full Text] [Related]
27. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma.
Du M; Peng H; Singh N; Isaacson PG; Pan L
Blood; 1995 Dec; 86(12):4587-93. PubMed ID: 8541549
[TBL] [Abstract][Full Text] [Related]
28. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
29. p53 expression, mutation, and allelic deletion in ovarian cancer.
McManus DT; Yap EP; Maxwell P; Russell SE; Toner PG; McGee JO
J Pathol; 1994 Nov; 174(3):159-68. PubMed ID: 7823248
[TBL] [Abstract][Full Text] [Related]
30. Mutation of tumor suppressor gene p53 is frequently found in vulvar carcinoma cells.
Hietanen SH; Kurvinen K; Syrjänen K; Grénman S; Carey T; McClatchey K; Syrjänen S
Am J Obstet Gynecol; 1995 Nov; 173(5):1477-82. PubMed ID: 7503188
[TBL] [Abstract][Full Text] [Related]
31. Expression of immunoglobulin heavy chain variable gene (VH) in B-chronic lymphocytic leukemia (B-CLL) and B-prolymphocytic leukemia (B-PLL) cell lines. "Restricted" usage of VH3 family.
Bertin PA; Marti GE
Ann N Y Acad Sci; 1992 May; 651():464-6. PubMed ID: 1318012
[No Abstract] [Full Text] [Related]
32. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.
Wattel E; Preudhomme C; Hecquet B; Vanrumbeke M; Quesnel B; Dervite I; Morel P; Fenaux P
Blood; 1994 Nov; 84(9):3148-57. PubMed ID: 7949187
[TBL] [Abstract][Full Text] [Related]
33. Significance of p53 mutations in patients with chronic lymphocytic leukemia: a sequential study of 30 patients.
Barnabas N; Shurafa M; Van Dyke DL; Wolman SR; Clark D; Worsham MJ
Cancer; 2001 Jan; 91(2):285-93. PubMed ID: 11180073
[TBL] [Abstract][Full Text] [Related]
34. p53 gene aberrations in non-small-cell lung carcinomas from a smoking population.
Liloglou T; Ross H; Prime W; Donnelly RJ; Spandidos DA; Gosney JR; Field JK
Br J Cancer; 1997; 75(8):1119-24. PubMed ID: 9099958
[TBL] [Abstract][Full Text] [Related]
35. p53 mutations and overexpressions in Japanese breast cancer.
Fukushima T; Onda M; Abe R; Otake T; Kimijima I; Tsuchiya A
Eur J Surg Oncol; 1995 Dec; 21(6):595-600. PubMed ID: 8631401
[TBL] [Abstract][Full Text] [Related]
36. Novel small deletions of the p53 gene in late-stage B-cell chronic lymphocytic leukaemia.
Gandini D; Aguiari GL; Cuneo A; Piva R; Castoldi GL; del Senno L
Br J Haematol; 1994 Dec; 88(4):881-5. PubMed ID: 7819113
[TBL] [Abstract][Full Text] [Related]
37. Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma.
Wagner SD; Martinelli V; Luzzatto L
Blood; 1994 Jun; 83(12):3647-53. PubMed ID: 8204889
[TBL] [Abstract][Full Text] [Related]
38. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
[TBL] [Abstract][Full Text] [Related]
39. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma.
Nishida N; Fukuda Y; Kokuryu H; Toguchida J; Yandell DW; Ikenega M; Imura H; Ishizaki K
Cancer Res; 1993 Jan; 53(2):368-72. PubMed ID: 8093350
[TBL] [Abstract][Full Text] [Related]
40. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
